This company listing is no longer active
GXE Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €44.47 |
| 52 Week High | €66.40 |
| 52 Week Low | €42.87 |
| Beta | 0.080 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -23.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 382.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| GXE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | -0.5% |
| 1Y | -24.0% | -6.0% | 15.5% |
Return vs Industry: GXE matched the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: GXE underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| GXE volatility | |
|---|---|
| GXE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: GXE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GXE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,357 | Paul Stoffels | www.glpg.com |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Galapagos NV Fundamentals Summary
| GXE fundamental statistics | |
|---|---|
| Market cap | €2.66b |
| Earnings (TTM) | €5.57m |
| Revenue (TTM) | €577.15m |
477.7x
P/E Ratio4.6x
P/S RatioIs GXE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXE income statement (TTM) | |
|---|---|
| Revenue | €577.15m |
| Cost of Revenue | €459.96m |
| Gross Profit | €117.19m |
| Other Expenses | €111.62m |
| Earnings | €5.57m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 23, 2023
| Earnings per share (EPS) | 0.085 |
| Gross Margin | 20.30% |
| Net Profit Margin | 0.96% |
| Debt/Equity Ratio | 0% |
How did GXE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/01 13:35 |
| End of Day Share Price | 2022/11/04 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galapagos NV is covered by 31 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| René Verhoef | ABN AMRO Bank N.V. |
| Emily Field | Barclays |
| Patrick Trucchio | Berenberg |